利妥昔单抗治疗免疫球蛋白介导的膜增生性肾小球肾炎的研究进展
Rituximab in the treatment of immunoglobulin-mediated membranoproliferative glomerulonephritis
张笑恬 1马雷雷 1支勇 1张微 1李静 1王耀光1
作者信息
- 1. 天津中医药大学第一附属医院国家中医针灸临床医学研究中心,天津 300381
- 折叠
摘要
膜增生性肾小球肾炎(MPGN)是以肾小球系膜细胞增生及系膜基质沿内皮细胞和毛细血管基底膜插入而形成"双轨征"为主要特征的肾脏病理类型,免疫球蛋白(包括免疫复合物、单克隆免疫球蛋白等)沉积是其损伤机制之一.该病主要临床表现为蛋白尿(多为大量蛋白尿)、高血压、肾性血尿及肾功能受损,且常伴有低补体血症,预后较差,现有诊疗方案对该病的疗效尚不确切.利妥昔单抗是一种抗B细胞表面抗原CD20的特异性人鼠嵌合型单克隆抗体.近年来,部分国内外学者将利妥昔单抗应用于免疫球蛋白介导的MPGN,本文对此进行总结,以期为免疫球蛋白介导的MPGN的临床治疗提供参考.
Abstract
Membranoproliferative glomerulonephritis(MPGN)is a renal pathological type characterized by the proliferation of mesangial cells and the insertion of mesangial matrix along endothelial cells and capillary basement membranes,forming a"double track sign".The deposition of immunoglobulins(including immune complexes,monoclonal immunoglobulins,etc.)is one of its damage mechanisms.The main clinical manifestations of this disease are proteinuria(mostly a large amount of proteinuria),hypertension,renal hematuria,and impaired renal function,often accompanied by hypocomplementaemia,with poor prognosis.The efficacy of existing diagnostic and treatment plans for this disease is still uncertain.Rituximab is a specific human mouse chimeric monoclonal antibody against the B-cell surface antigen CD20.In recent years,some domestic and foreign scholars have applied rituximab to immunoglobulin mediated MPGN.Therefore,this article summarizes this in order to provide reference for the clinical treatment of immunoglobulin mediated MPGN.
关键词
膜增生性肾小球肾炎/利妥昔单抗/免疫球蛋白沉积/免疫复合物/单克隆免疫球蛋白/丙型肝炎病毒/自身免疫性疾病Key words
Membranoproliferative glomerulonephritis/Rituximab/Immunoglobulin deposition/Immune complexes/Monoclonal immunoglobulin/Hepatitis C virus/Autoimmune diseases引用本文复制引用
基金项目
国家自然科学基金(82004316)
国家自然科学基金(81473447)
出版年
2024
NETL
NSTL
万方数据